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Abstract Human cytomegalovirus (HCMV) is an impor-
tant opportunistic pathogen in immunocompromised
patients and a major cause of congenital birth defects when
acquired in utero. In the 1990s, four chimeric viruses were
constructed by replacing genome segments of the high
passage Towne strain with segments of the low passage
Toledo strain, with the goal of obtaining live attenuated
vaccine candidates that remained safe but were more
immunogenic than the overly attenuated Towne vaccine.
The chimeras were found to be safe when administered to
HCMV-seronegative human volunteers, but to differ sig-
nificantly in their ability to induce seroconversion. This
suggests that chimera-specific genetic differences impacted
the ability to replicate or persist in vivo and the consequent
ability to induce an antibody response. To identify specific
genomic breakpoints between Towne and Toledo
sequences and establish whether spontaneous mutations or
rearrangements had occurred during construction of the
chimeras, complete genome sequences were determined.
No major deletions or rearrangements were observed,
although a number of unanticipated mutations were iden-
tified. However, no clear association emerged between the
genetic content of the chimeras and the reported levels of
vaccine-induced HCMV-specific humoral or cellular
immune responses, suggesting that multiple genetic deter-
minants are likely to impact immunogenicity. In addition to
revealing the genome organization of the four vaccine
candidates, this study provided an opportunity to probe the
genetics of HCMV attenuation in humans. The results may
be valuable in the future design of safe live or replication-
defective vaccines that optimize immunogenicity and
efficacy.
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Human cytomegalovirus (HCMV) infections are an
important cause of birth defects among newborns infected
in utero and of morbidity and mortality in transplant and
AIDS patients. Despite receiving the US Institute of
Medicine’s highest priority designation in 2000 [1], and
after half a century of research, development of an HCMV
vaccine remains an unmet medical need of considerable
importance to public health.
Among the first HCMV vaccine candidates was the live
attenuated strain Towne vaccine produced by[125 pas-
sages in cultured human fibroblasts [2]. This vaccine has
been administered safely to nearly 1000 human subjects at
doses as high as 3000 plaque-forming units (pfu), and has
never been recovered from an immunized subject, even
following immune suppression [3–5]. In contrast, the
Toledo strain passaged only four or five times in cultured
fibroblasts exhibited virulence characteristics in HCMV-
seronegative volunteers at a dose of only 10 pfu [6], and
was capable of superinfection, replicating, and persisting in
the context of pre-existing natural immunity [6, 7].
Although administration of Towne vaccine prior to renal
transplantation reduced post-transplant HCMV-associated
disease, it did not prevent HCMV infections [3], and it
failed to protect immunocompetent mothers from acquiring
HCMV infections from their children [8]. These results
suggest that the immunogenicity of the Towne vaccine may
be overly attenuated due to mutations acquired during
serial passage in vitro [9–11].
With the goal of increasing the immunogenicity of the
Towne vaccine, four genetic chimeras were constructed by
systematically replacing Towne genome segments with
segments from Toledo [12]. Each chimera was shown to be
safe when administered at a dose of 1000 pfu to healthy
HCMV-seropositive human volunteers. However, failure to
recover any chimera from blood, urine, or saliva following
inoculation, combined with the inability of the chimeras to
boost humoral or cellular immune responses, suggested
that none retained the superinfection properties of the
Toledo strain [12].
A phase 1 trial of the four chimeras in healthy HCMV-
seronegative subjects was recently completed [13]. Each
vaccine was administered to a total of nine subjects, with
groups of three subjects receiving doses of 10, 100, or 1000
pfu by the subcutaneous route. There were neither local nor
systemic reactions nor serious adverse events, and none of
the subjects shed infectious virus in urine or saliva. In
general, cellular and humoral immune responses were
comparable to those reported previously for the Towne
vaccine, and none of the chimeras appeared to be more
virulent or immunogenic than the Towne vaccine. How-
ever, with regard to seroconversion, chimeras 2 and 4 were
clearly more immunogenic than chimeras 1 or 3: seven of
the nine subjects who received chimera 4 seroconverted, as
did three of the nine subjects who received chimera 2,
while only one of the nine subjects who received chimera 1
seroconverted, and none of the nine subjects who received
chimera 3 seroconverted [13].
These results suggest that genetic differences among the
four chimeras significantly impacted their ability to repli-
cate or persist in vivo to an extent necessary to induce an
antibody response. Although the approximate locations of
junctions between Towne and Toledo sequences in the
chimeras have been reported [12], the precise breakpoints
and any spontaneous mutations that may have arisen during
recombinant virus construction were unknown. Therefore,
we determined the complete sequences of all four
chimeras.
Table 1 summarizes genome information for the chi-
meras and complete (or substantially complete) Towne and
Toledo sequences that were derived previously or during
the present study. The Towne genomes represent two major
variants, of which varS, in comparison with varL, has a
large deletion at the right end of the UL region (commonly
called UL/b
0 [11]) associated with an inverted duplication
of a sequence from the left end of UL [9]. Passage of
HCMV in cell culture is known invariably to result in
mutation of RL13 and also of UL128, UL130, or UL131A
[14–16], the latter three genes encoding subunits of a
pentameric complex necessary for efficient entry of HCMV
into cells of the epithelial, endothelial, or myeloid lineages
[17–22]. Towne is mutated in RL13 and UL130, as well as
in UL1, UL40, and US1 [9, 10], and the form of varS from
which the chimeras were derived is also mutated in UL36
[23]. Toledo is mutated in RL13 and UL128 (the latter by
the inversion of a large region of the genome) [11, 24, 25],
as well as in UL9. Mapping the components of the chi-
meras was informed in particular by accessions FJ616285
and GQ121041 for Towne [9, 10] and accessions
GU937742 and KY002201 for Toledo. GU937742 repre-
sents the standard form of Toledo from which the chimeras
were derived (at passage 8), and KY002201 represents a
variant (obtained via transfection of a Toledo DNA stock
followed by plaque purification) that has a different
mutation in gene RL13. The fact that more than one RL13
mutant was selected during isolation of Toledo is consis-
tent with similar observations made with other strains, and
indicates that adaptation of wild-type HCMV to cell culture
involves a complex, gradual process of genetic selection
[14–16]. Thus, both Towne and Toledo apparently carried
mutations that had accumulated due to passage in
fibroblasts.
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The genetic maps of the chimeras are shown in Fig. 1a.
The parental strains are both nonepitheliotropic and
nonendotheliotropic due to the mutations disrupting
expression of UL130 (Towne) or UL128 (Toledo)
[10, 17, 26]. The consequent failure to express a functional
pentameric complex is speculated to contribute to attenu-
ation of the Towne vaccine by limiting the range of host
cell types available for replication in vivo, and to Towne’s
insufficient efficacy, as the pentameric complex is an
important immunogen for eliciting antibodies that neu-
tralize the entry of HCMV into cells of the epithelial,
endothelial, and myeloid lineages [22, 27–29].
By design [12], all four chimeras contain Toledo UL/b
0
and within this a disrupted copy of UL128. However, prior
to the present study, it was unclear whether chimeras 1 and
2 might contain an intact copy of UL128 within the
upstream Towne sequences, potentially rendering them
epitheliotropic and endotheliotropic. However, as the
sequence data indicate that Towne UL128 is absent from
all four chimeras, none of them is genetically capable of
expressing a functional UL128 protein or pentameric
complex, even though the UL130 and UL131A proteins,
which contain neutralizing epitopes [30], may be expres-
sed. Consistent with this, phenotypic analysis revealed that
all four chimeras fail to enter ARPE-19 epithelial cells
efficiently (Fig. 1b; [31]). By extension, the inability to
express the pentameric complex is consistent with the
phase 1 trial findings that the chimera vaccines induced
neutralizing titers to entry into epithelial cells similar to
those of Towne and significantly lower than those induced
by natural infection [13]. In addition to the previously
recognized mutations in the parental strains, the sequences
revealed three novel mutations. The first disrupts UL147A
in chimera 4, the second is a short duplication within the
Towne-derived noncoding RNA4.9 in chimeras 1, 3, and 4
(with two duplications in chimera 4), and the third is an
intragenic deletion between US34A and TRS1 in chimera
1. A few other minor differences were also noted, as
specified in the legend to Fig. 1.
Examination of the mutations highlighted in Fig. 1a
revealed no obvious association between the presence of
particular mutations and the efficacy of the chimeras in
inducing seroconversion. For example, the fact that chi-
meras 2 and 3 contain the same mutations except for one
impacting UL40 might suggest that an inability to express
UL40 renders chimera 3 unable to induce seroconversion.
However, the same mutation is present in chimera 4, which
is the most immunogenic of the vaccines. Indeed, each of
the mutations present in chimera 3 is also present in
immunogenic chimeras 2 or 4. Therefore, the ability to
induce seroconversion is likely associated with the distri-
bution of parental sequences among the chimeras rather
than with specific mutations. For example, sequences from
US16 to the right genome terminus are derived from
Table 1 Partial and complete
genome sequences of HCMV
strains Towne and Toledo
Strain Genome Accession Size (bp) Release date References
Towne BAC varS AC146851 229,483 14-Oct-2003 [33]
Towne BAC varS AY315197 222,047 01-Dec-2003 [34]
Towne Virus varL FJ616285 235,147 07-Feb-2009 [9]
Towne BAC varL GQ121041 238,311 17-Jun-2009 [10]
Towne BAC mutant (UL96) varS KF493877 233,028 18-Aug-2013 [35]
Towne Virus mutant (UL96) varS KF493876 232,948 18-Aug-2013 [36]
Toledo BAC AC146905 226,889 21-Oct-2003 [33]
Toledo Virus AH013698 158,133 08-Mar-2004 [36]
Toledo Virus GU937742 235,404 10-Mar-2010 Present work
Toledo Virus variant KY002201 235,681 15-Nov-2016 Present work
Toledo Virus mutant (RNA2.7) KY002200 233,779 15-Nov-2016 Present work
Towne/Toledo Virus chimera 1 KX101021 235,882 08-Jun-2016 Present work
Towne/Toledo Virus chimera 2 KX101022 234,441 08-Jun-2016 Present work
Towne/Toledo Virus chimera 3 KX101023 235,354 08-Jun-2016 Present work
Towne/Toledo Virus chimera 4 KX101024 236,269 08-Jun-2016 Present work
Genomes were sequenced as bacterial artificial chromosomes (BACs), viruses, virus variants, virus
mutants, or virus chimeras, and in varS or varL form for Towne. The two Towne BAC varS sequences
describe the same BAC but differ in size because they lack different parts of the vector. The chimeras that
had been used to inoculate seronegative human subjects [13] were amplified by passaging twice in MRC-5
human fibroblast cells, and virion DNA was isolated from culture supernatants as described previously [37].
Sequence data were obtained for these and the other viruses examined in the present work using the
Illumina MiSeq platform, and assembled and validated as described previously [38]. Additional informa-
tion is available in the GenBank accessions
652 Virus Genes (2017) 53:650–655
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Toledo in chimera 4 and from Towne in the other chimeras.
This region contains immune evasion genes [32] and per-
haps other elements that may contribute to the relatively
enhanced immunogenicity of chimera 4.
Although the phase 1 chimera trial did not include
Towne vaccine, comparison to historical data suggested
that all four chimeras are attenuated to a level similar to
that of the Towne vaccine [13]. This indicates that the
virulence characteristics associated with Toledo are mul-
tifactorial, in that none of the Toledo sequences appeared
measurably to enhance virulence when inserted into the
Towne genome. Alternatively, it is possible that the RL13
or UL128 mutations present in Toledo passage 8 and the
chimeras did not fully pervade the viral population present
in the Toledo passage 4 or 5 stocks that proved virulent in
humans; that is, that some unmutated virus may have
remained at this stage and was responsible for the biolog-
ical effect. Unfortunately, Toledo passage 8 has not been
tested in humans, and samples of earlier passages are no
longer available.
The construction and testing of the four chimeric vac-
cine candidates has provided a rare opportunity to study the
A
B
MRC-5
ARPE-19
Chimera 4Chimera 3Chimera 2Chimera 1TS15TS15-rNBADrUL131mock
Efficacy 
(% sero- 
conversion)
Towne sequences Toledo sequences ORFs containing disruptive mutations
Chimera 4
UL9 UL128 RL13
two duplications within RNA4.9
UL32 UL36 UL40 UL102 UL147A 
78%
Chimera 3
US16UL128 RL13 UL70
duplication within RNA4.9
UL1 UL36 UL40
0%
Chimera 2
UL1 US16UL128 RL13 UL36 UL86 UL133
33%
Chimera 1
a sequence
UL9
inversion
c sequence
US16
a' sequence a sequence
RL11 UL128 UL133RL13 TRS1
c' sequence
IRS1RNA4.9OriLytUL54
duplication within RNA4.9
11%
Fig. 1 a Sequence-based genetic maps of the four Towne/Toledo
chimera vaccine strains. Open arrows indicate open reading frames,
and lines with arrowheads indicate noncoding RNAs. Tall rectangles
indicate inverted repeats (a/a0 and c/c0), and these and other features
(oriLyt, RNA4.9, IRS1, and TRS1) are labeled on chimera 1. Genes
containing disrupting mutations are labeled in red, and genes located
at breakpoints are labeled in black (these include UL36 in chimera 2).
Additional differences among regions derived from the same original
strain are not marked. These include a large noncoding deletion
between US34A and TRS1 in chimera 2, a small noncoding deletion
between UL150A and IRS1 in chimera 3, a short region of Towne
sequence at the beginning of the Toledo a0 sequence in chimera 2
(probably as a result of recombination), a few differences in the
lengths of noncoding G:C tracts, three substitutions in intergenic
regions (UL102/UL103 and UL124/UL128 in chimera 1, and UL23/
UL24 in chimera 4), one substitution in RNA5.0 in chimera 2, two
synonymous substitutions in coding regions (UL10 and TRS1 in
chimera 1), four nonsynonymous substitutions (UL11 and US10 in
chimera 1, UL47 in chimera 2, and UL93 in chimera 4), and a small
number (2–6 per genome) of nucleotide polymorphisms. The
recombinational breakpoints in US16 in chimeras 1, 2, and 3 are
located within a 255 bp sequence that is identical in Towne and
Toledo. The values on the right indicate the relative immunogenicity
levels of each chimera reported previously [13]. b MRC-5 fibroblast
or ARPE-19 epithelial cells were mock-infected or infected with
equivalent amounts of the indicated viruses and after 4 d stained for
HCMV immediate early proteins as described previously [27].
BADrUL131 and TS15-rN are epitheliotropic variants of HCMV
strains AD169 and Towne varS, respectively [26, 39], and TS15 is a
nonepitheliotropic variant of Towne varS [10] (Colour figure online)
Virus Genes (2017) 53:650–655 653
123
genetics of viral pathogenesis in humans. While no specific
virulence gene emerged from this limited study, the data
suggest that relatively few genetic changes are capable of
producing a virus that is highly attenuated and yet capable
of replicating in vivo to an extent required to induce both
humoral and cellular immune responses. These findings
may be valuable for rationally designing live attenuated or
replication-defective vaccines that maximize safety while
optimizing immunogenicity and efficacy.
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